Drugs / R(+)XK469
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00095797 | Oct 2004 → Mar 2007 | B-cell chronic lymphocytic leukemia, acute basophilic leukemia, acute erythroid leukemia, acute megakaryoblastic leukemia in adult +13 | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00028548 | Jan 2002 → Dec 2006 | cancer of unknown primary site | Barbara Ann Karmanos Cancer Institute | Completed | No outcome recorded |
| Phase 1 | NCT00028522 | Dec 2001 → Sep 2009 | neuroblastoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | R(+)XK469 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00095797 ↗ |
| Known as | NSC 698215 | “Phase I Study of R(+)-XK469 (NSC 698215) Given Daily, Days 1-5, Repeated Every Three Weeks in Patients With Advanced Malignancies” NCT00028548 ↗ |
| Modality | Small molecule | — CHEMBL1741037 ↗ |
| Route | Intravenous | “Patients receive R(+)XK469 intravenously (IV) over 30 minutes on days 1, 3, and 5.” NCT00028522 ↗ |